CLE-100 / Clexio Biosci - LARVOL DELTA

SOLEO: A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Clexio Biosciences Ltd.

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study (clinicaltrials.gov) - P2 | N=130 | Completed | Sponsor: Clexio Biosciences Ltd. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study (clinicaltrials.gov) - P2 | N=130 | Active, not recruiting | Sponsor: Clexio Biosciences Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study (clinicaltrials.gov) - P2; N=137; Recruiting; Sponsor: Clexio Biosciences Ltd.; Trial completion date: Jul 2022 ➔ Nov 2022; Trial primary completion date: Jun 2022 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study (clinicaltrials.gov) - P2; N=137; Recruiting; Sponsor: Clexio Biosciences Ltd.; Trial completion date: Nov 2021 ➔ Jul 2022; Trial primary completion date: Nov 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study (clinicaltrials.gov) - P2; N=137; Recruiting; Sponsor: Clexio Biosciences Ltd.; N=15 ➔ 137

Clinical • Enrollment change • CNS Disorders • Depression • Mood Disorders • Psychiatry

CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study (clinicaltrials.gov) - P2; N=15; Recruiting; Sponsor: Clexio Biosciences Ltd.; Trial completion date: Jan 2020 ➔ Nov 2021; Trial primary completion date: Jan 2020 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders

[VIRTUAL] Low-level pulsed wave red light induces type I procollagen protein and ATP production at shorter treatment times as compared to continuous wave red light (SID 2020) - "Treatment with PW red light at 0.3 J/cm2 (8 mW/cm2 with 500 Hz or 800 Hz for 100 seconds, duty cycle 40%) significantly increased procollagen type I production in human fibroblasts, similarly to CW red light at 0.3 J/cm2 (0.5 mW/cm2 for 10 minutes, duty cycle 100%)...In conclusion, low-level pulsed wave red light induced biomodulation in human fibroblasts at a significantly shorter treatment time than continuous wave light. Thus, a non-continuous, pulsed wave light mode delivering similar benefits in a significantly shorter exposure time may have substantial advantage for consumer compliance and convenience, enhancing therapeutic value for skin rejuvenation, wound-healing and pain management."

Fibrosis • Immunology • Pain • COL1A2

In-vitro retention force changes during cyclic dislodging of three novel attachment systems for implant overdentures with different implant angulations. (PubMed, Clin Oral Implants Res) - "All systems showed retentive forces promising successful clinical use in implant overdentures, even in situations with extremely angulated implants. Specific abutments compensating interimplant angulation maintain retention longer in situations with high axe divergencies."

Journal • Preclinical

SPECIFITY OF VENTRICULAR TACHYCARDIA SUBSTRATES IN ISCHEMIC AND DILATIVE CARDIOMYOPATHIES: PATTERNS OF CARDIAC FIBROSIS AND VENTRICULAR REPOLARIZATION (IDSS 2020) - "Pts with ischemic and dilated cardiomyopathies need different approaches for identification of VTs substrate."

MRI

"Saw a pt post Cycle 100 Nivo. Was hospice 5yrs ago, started on compassionate grounds. Miracle indeed #Immunotherapy #nivolumab #OncologyMiracle #miracle @houseinsater @ZakhariaYousef @GACancerCenter @GCC_Cortes @AlDallasGCC" (@sarfee)

"Can I like this article 100 times please! 👏🏾👏🏾👏🏾 @MKIttlesonMD @atunuguntla1" (@cardiojaydoc02)